Literature DB >> 24085502

Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT.

Axel Wetter1, Christine Lipponer, Felix Nensa, Philipp Heusch, Herbert Rübben, Jens-Christian Altenbernd, Thomas Schlosser, Andreas Bockisch, Thorsten Pöppel, Thomas Lauenstein, James Nagarajah.   

Abstract

PURPOSE: The aim of this study was to evaluate the positron emission tomography (PET) component of [(18)F]choline PET/MRI and compare it with the PET component of [(18)F]choline PET/CT in patients with histologically proven prostate cancer and suspected recurrent prostate cancer.
METHODS: Thirty-six patients were examined with simultaneous [(18)F]choline PET/MRI following combined [(18)F]choline PET/CT. Fifty-eight PET-positive lesions in PET/CT and PET/MRI were evaluated by measuring the maximum and mean standardized uptake values (SUVmax and SUVmean) using volume of interest (VOI) analysis. A scoring system was applied to determine the quality of the PET images of both PET/CT and PET/MRI. Agreement between PET/CT and PET/MRI regarding SUVmax and SUVmean was tested using Pearson's product-moment correlation and Bland-Altman analysis.
RESULTS: All PET-positive lesions that were visible on PET/CT were also detectable on PET/MRI. The quality of the PET images was comparable in both groups. Median SUVmax and SUVmean of all lesions were significantly lower in PET/MRI than in PET/CT (5.2 vs 6.1, p<0.05 and 2.0 vs 2.6, p<0.001, respectively). Pearson's product-moment correlation indicated highly significant correlations between SUVmax of PET/CT and PET/MRI (R=0.86, p<0.001) as well as between SUVmean of PET/CT and PET/MRI (R=0.81, p<0.001). Bland-Altman analysis revealed lower and upper limits of agreement of -2.77 to 3.64 between SUVmax of PET/CT vs PET/MRI and -1.12 to +2.23 between SUVmean of PET/CT vs PET/MRI.
CONCLUSION: PET image quality of PET/MRI was comparable to that of PET/CT. A highly significant correlation between SUVmax and SUVmean was found. Both SUVmax and SUVmean were significantly lower in [(18)F]choline PET/MRI than in [(18)F]choline PET/CT. Differences of SUVmax and SUVmean might be caused by different techniques of attenuation correction. Furthermore, differences in biodistribution and biokinetics of [(18)F]choline between the subsequent examinations and in the respective organ systems have to be taken into account.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24085502     DOI: 10.1007/s00259-013-2560-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  20 in total

1.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

Authors:  Mohsen Beheshti; Larisa Imamovic; Gabriele Broinger; Reza Vali; Peter Waldenberger; Franz Stoiber; Michael Nader; Bernhard Gruy; Guenter Janetschek; Werner Langsteger
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

Review 2.  Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques.

Authors:  Matthias Hofmann; Bernd Pichler; Bernhard Schölkopf; Thomas Beyer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

3.  MRI-guided attenuation correction in whole-body PET/MR: assessment of the effect of bone attenuation.

Authors:  A Akbarzadeh; M R Ay; A Ahmadian; N Riahi Alam; H Zaidi
Journal:  Ann Nucl Med       Date:  2012-12-21       Impact factor: 2.668

4.  Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT.

Authors:  Marco Wiesmüller; Harald H Quick; Bharath Navalpakkam; Michael M Lell; Michael Uder; Philipp Ritt; Daniela Schmidt; Michael Beck; Torsten Kuwert; Carl C von Gall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-06       Impact factor: 9.236

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

Authors:  Ronald Boellaard; Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

7.  Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.

Authors:  Philipp Heusch; Christian Buchbender; Karsten Beiderwellen; Felix Nensa; Verena Hartung-Knemeyer; Thomas C Lauenstein; Andreas Bockisch; Michael Forsting; Gerald Antoch; Till A Heusner
Journal:  Eur J Radiol       Date:  2013-02-08       Impact factor: 3.528

8.  Comparison of standardized uptake values in normal structures between PET/CT and PET/MRI in an oncology patient population.

Authors:  Sharif Kershah; Sasan Partovi; Bryan J Traughber; Raymond F Muzic; Mark D Schluchter; James K O'Donnell; Peter Faulhaber
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

9.  A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients.

Authors:  Augusto Giussani; Tilman Janzen; Helena Uusijärvi-Lizana; Federico Tavola; Maria Zankl; Marie Sydoff; Anders Bjartell; Sigrid Leide-Svegborn; Marcus Söderberg; Sören Mattsson; Christoph Hoeschen; Marie-Claire Cantone
Journal:  J Nucl Med       Date:  2012-05-08       Impact factor: 10.057

10.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

Authors:  Marino Cimitan; Roberto Bortolus; Sandro Morassut; Vincenzo Canzonieri; Antonio Garbeglio; Tanja Baresic; Eugenio Borsatti; Annalisa Drigo; Mauro G Trovò
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

View more
  18 in total

Review 1.  Clinical oncologic applications of PET/MRI: a new horizon.

Authors:  Sasan Partovi; Andres Kohan; Christian Rubbert; Jose Luis Vercher-Conejero; Chiara Gaeta; Roger Yuh; Lisa Zipp; Karin A Herrmann; Mark R Robbin; Zhenghong Lee; Raymond F Muzic; Peter Faulhaber; Pablo R Ros
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

2.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

3.  Diagnostic value of retrospectively fused 64CuCl2 PET/MRI in biochemical relapse of prostate cancer: comparison with fused 18F-Choline PET/MRI, 64CuCl2 PET/CT, 18F-Choline PET/CT, and mpMRI.

Authors:  Francesco Paparo; Alice Peirano; João Matos; Lorenzo Bacigalupo; Umberto Rossi; Ilaria Mussetto; Gianluca Bottoni; Martina Ugolini; Carlo Introini; Filippo Grillo Ruggieri; Gian Andrea Rollandi; Arnoldo Piccardo
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 4.  Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Authors:  M Picchio; P Mapelli; V Panebianco; P Castellucci; E Incerti; A Briganti; G Gandaglia; M Kirienko; F Barchetti; C Nanni; F Montorsi; L Gianolli; S Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-17       Impact factor: 9.236

Review 5.  18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.

Authors:  Claudio Spick; Ken Herrmann; Johannes Czernin
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

Review 6.  Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.

Authors:  Kazuhiro Kitajima; Yasuhiko Ebina; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2014-04-18       Impact factor: 2.374

Review 7.  Clinical applications of PET/MRI: current status and future perspectives.

Authors:  Felix Nensa; Karsten Beiderwellen; Philipp Heusch; Axel Wetter
Journal:  Diagn Interv Radiol       Date:  2014 Sep-Oct       Impact factor: 2.630

Review 8.  Update on advances in molecular PET in urological oncology.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Kazuhito Fukushima; Ryogo Minamimoto; Takao Kamai; Hossein Jadvar
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

9.  Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tübingen, Germany.

Authors:  D L Bailey; G Antoch; P Bartenstein; H Barthel; A J Beer; S Bisdas; D A Bluemke; R Boellaard; C D Claussen; C Franzius; M Hacker; H Hricak; C la Fougère; B Gückel; S G Nekolla; B J Pichler; S Purz; H H Quick; O Sabri; B Sattler; J Schäfer; H Schmidt; J van den Hoff; S Voss; W Weber; H F Wehrl; T Beyer
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

10.  Value of fused 18F-Choline-PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results.

Authors:  Arnoldo Piccardo; Francesco Paparo; Riccardo Piccazzo; Riccardo Picazzo; Mehrdad Naseri; Paolo Ricci; Andrea Marziano; Lorenzo Bacigalupo; Ennio Biscaldi; Gian Andrea Rollandi; Filippo Grillo-Ruggieri; Mohsen Farsad
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.